New Approaches to the Removal of Protein-Bound Toxins from Blood Plasma of Uremic Patients

REFERENCES

• Boure, T., Vanholder, R. (2004). Biochemical and clinical evidence for uremic toxicity. Artif. Organs. 28: 248–253.
   Google Scholar
• Sudlow, G., Birkett, D.J., Wade, D.N. (1976). Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12: 1052–1061.
   PubMed Web of Science ®Google Scholar
• Dasgupta, A., Paul, A., Wells, A. (2001). Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am. J. Med. Sci. 322: 204–208.
   Google Scholar
• Sakai, T., Yamasaki, K., Sako, T., Kragh-Hansen, U., Suenaga, A., Otagiri, M. (2001). Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm. Res. 18: 520–524.
   PubMed Web of Science ®Google Scholar
• Viani, A., Rizzo, G., Carrai, M., Pacifici, G.M. (1992). The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol. 33: 299–304.
   PubMed Web of Science ®Google Scholar
• Mabuchi, H., Nakahashi, H. (1988). Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum. Ther. Drug Monit. 10: 261–264.
   Google Scholar
• Calvo, R., Carlos, R., Erill, S. (1985). Underestimation of albumin content by bromocresol green, induced by drug displacers and uremia. Int. J. Clin. Pharmacol. Ther. Toxicol. 23: 76–78.
   Google Scholar
• Priborsky, J., Takayama, K., Nagai, T. (1998). Influence of acute uraemia on percutaneous absorption of nonsteroidal anti-inflammatory drugs. Acta. Univ. Palacki. Olomuc. Fac. Med. 41: 35–38.
   Google Scholar
• Vanholder, R., Glorieux, G., Lameire, N. (2005). New insights in uremic toxicity. Contrib. Nephrol. 149: 315–324.
   PubMed Web of Science ®Google Scholar
• Sakai, T., Takadate, A., Otagiri, M. (1995). Characterization of binding site of uremic toxins on human serum albumin. Biol. Pharm. Bull. 18: 1755–1761.
   PubMedGoogle Scholar
• Tsutsumi, Y., Deguchi, T., Takano, M., Takadate, A., Lindup, W.E., Otagiri, M. (2002). Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. J. Pharmacol. Exp. Ther. 303: 880–887.
   PubMed Web of Science ®Google Scholar
• Henderson, S.J., Lindup, W.E. (1992). Renal organic acid transport: Uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J. Pharmacol. Exp. Ther. 263: 54–60.
   Google Scholar
• Lim, C.F., Bernard, B.F., de Jong, M., Docter, R., Krenning, E.P., Hennemann, G. (1993). A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J. Clin. Endocrinol. Metab. 76: 318–324.
   PubMed Web of Science ®Google Scholar
• Niwa, T., Yazawa, T., Kodama, T., Uehara, Y., Maeda, K., Yamada, K. (1990). Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56: 241–245.
   Google Scholar
• Takamura, N., Maruyama, T., Otagiri, M. (1997). Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. Clin. Chem. 43: 2274–2280.
   PubMed Web of Science ®Google Scholar
• Niwa, T., Ise, M., Miyazaki, T. (1994). Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am. J. Nephrol. 14: 207–212.
   PubMed Web of Science ®Google Scholar
• Lim, C.F., Bernard, B.F., de Jong, M., Docter, R., Krenning, E.P., Hennemann, G. (1993). A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J. Clin. Endocrinol. Metab. 76: 318–324.
   PubMed Web of Science ®Google Scholar
• Kawashima, Y. (1989). Study on the uremic protein binding inhibitors as uremic toxin: Toxic effect on erythroid colony formation, lymphocyte blast formation and renal function. Nippon. Jinzo. Gakkai. Shi. 31: 1151–1161.
   Google Scholar
• McNamara, P.J., Lalka, D., Gibaldi, M. (1981). Endogenous accumulation products and serum protein binding in uremia. J. Lab. Clin. Med. 98: 730–740.
   Google Scholar
• Bowmer, C.J., Lindup, W.E. (1982). Decreased drug binding in uraemia: Effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem. Pharmacol. 31: 319–323.
   Google Scholar
• Ikeda, K., Yoshitomi, H., Nakayama, T., Goto, S., Kimura, T. (1984). Plasma protein binding of frusemide in renal failure rabbits: Investigation of endogenous protein binding inhibitors. J. Pharm. Pharmacol. 36: 663–667.
   Google Scholar
• Niwa, T., Takeda, N., Tatematsu, A., Maeda, K. (1988). Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin. Chem. 34: 2264–2267.
   PubMed Web of Science ®Google Scholar
• Sarnatskaya, V.V., Lindup, W.E., Niwa, T., Ivanov, A.I., Yushko, L.A., Tjia, J., Maslenny, V.N., Korneeva, L.N., Nikolaev, V.G. (2002). Effect of protein-bound uremic toxins on the thermodynamic characteristics of human albumin. Biochem. Pharmacol. 63: 1287–1296.
   PubMedGoogle Scholar
• Nikolaev, V.G., Sarnatskaya, V.V., Bardakhyvskaya, K.I., Susak, Ya. M., Snejkova, E.A., Chernomyz, V.D., Tsymbalyuk, R.S., Uvarov, V.Yu., Gurina, N.M. (2003). Efferent Therapy 9: 26–39 (in Russian).
   Google Scholar
• Coassolo, P., Sarrazin, M., Sari, J.C., Briand, C. (1978). Microcalorimetric studies on the binding of some benzodiazepine derivatives to human serum albumin. Biochem. Pharmacol. 27: 2787–2792.
   PubMed Web of Science ®Google Scholar
• Vasileva, R., Jakab, M., Hasko, F. (1981). Application of ion-exchange chromatography for the production of human albumin. J. Chromatogr. 30: 279–284.
   Google Scholar
• Sarnatskaya, V.V., Ivanov, A.I., Nikolaev, V.G., Rotellar, E., von Appen, K., Haspar, M., Maslenny, V.N., Klinkmann, H. (1998). Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis. Artif. Organs. 22: 107–115.
   Google Scholar
• Port, F.K. (1994). Morbidity and mortality in dialysis patients. Kidney Int. 46: 1728–1737.
   Google Scholar
• Daugirdas, J.T., Schneditz, D. (1995). Protein bound toxins in uremia. ASAIO J. 41: M719–M724.
   PubMedGoogle Scholar
• Vanholder, R., De Smet, R., Glorieux, G., Argiles, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P.P., Deppisch, R., Descamps-Latscha, B., Henle, T., Jorres, A., Lemke, H.D., Massy, Z.A., Passlick-Deetjen, J., Rodriguez, M., Stegmayr, B., Stenvinkel, P., Tetta, C., Wanner, C., Zidek, W. (2003). European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63: 1934–1943.
   PubMed Web of Science ®Google Scholar
• Ward, R.A. (2005). Protein-leaking membranes for hemodialysis: A new class of membranes in search of an application? J. Am. Soc. Nephrol. 16: 2421–2430.
   Google Scholar
• Ivanov, A.I., Sarnatskaya, V.V., Maslenny, V.N. (1997). Comparative study of albumin termodynamic parameters in ESRD patients treated by HD and CAPD. Abstracts of 3rd Intern. Symp. on Uremic Toxicity, Nagoya, Japan, 175.
   Google Scholar
• Chen, R.F. (1967). Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 242: 173–181.
   PubMed Web of Science ®Google Scholar
• Nascimento, M.M., Pasqual, D.D., dos Santos, J.E., Riella, M.C. (2002). Six years of treatment with the HELP system of a patient with familial hypercholesterolemia. Braz. J. Med. Biol. Res. 35: 775–782.
   Google Scholar
• Sarnatskaya, V.V., Lindup, W.E., Walther, P., Maslenny, V.N., Yushko, L.A., Sidorenko, A.S., Nikolaev, A.V., Nikolaev, V.G. (2002). Albumin, bilirubin, and activated carbon: New edges of an old triangle. Artif. Cells Blood Substit. Immobil. Biotechnol. 30: 113–126.
   Web of Science ®Google Scholar
• Certificate of the state registration, number 2647/2004 on 26.03.2004.
   Google Scholar
• Agalou, S., Ahmed, N., Thornalley, P.J., Dawnay, A. (2005). Advanced glycation end product free adducts are cleared by dialysis. Ann. N. Y. Acad. Sci. 1043: 734–739.
   Google Scholar
• Yang, X.B., Hou, F.F., Wu, Q., Zhou, H., Liu, Z.R., Yang, Y., Zhang, X. (2005). Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease. Zhonghua Nei Ke Za Zhi 44: 342–346.
   Google Scholar